VICTAS Trial: Vitamin C, Thiamine, and Hydrocortisone in Sepsis

victas trial vitamin c thiamine sepsis
2021 VICTAS TRIAL IM Effect of vitamin C, thiamine, and hydrocortisone on ventilator-and vasopressor-free days in patients with sepsis multicenter, double-blind, randomized controlled trial Objective: To determine whether combination of vitamin C, thiamine & hydrocortisone every 6 hours increases ventilator- and vasopressor-free days compared with placebo in patients with sepsis. 501 Patients Inclusion criteria: Patients aged ≥ 18 years with acute respiratory and/or cardiovascular dysfunction attributed to sepsis with planned ICU admission Intervention (Vit C, thiamine & hydrocortisone) group [n=252] 25 25 VS Control group [n=249] PRIMARY OUTCOME Ventilator & vasopressor free days Diff -1; 95% CI, -4 to 2; P=0.85 26 SECONDARY OUTCOMES 20.6 Mortality before ICU discharge % Diff 0.9; 95% CI, -8.0 to 6.1; P=0.79 19.7 40.5 Mortality at 180 days % 37.8 Diff 2.7; 95% CI, -11.3 to 5.8; P=0.53 10 10 Length of hospital stay (in days) Diff 1.0; 95% CI, -3.0 to 2.0; P=0.66 9 Conclusion: Among critically ill patients with sepsis, treatment with vitamin C, thiamine, and hydrocortisone, compared with placebo, did not significantly increase ventilator- and vasopressor-free days within 30 days. JE Sevransky et al. JAMA 2021; 325(8):742-750


Comments are closed.